A detailed history of Schonfeld Strategic Advisors LLC transactions in Merus N.V. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 6,000 shares of MRUS stock, worth $283,140. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,000
Previous 26,900 77.7%
Holding current value
$283,140
Previous $1.21 Million 70.69%
% of portfolio
0.0%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$39.81 - $60.2 $832,029 - $1.26 Million
-20,900 Reduced 77.7%
6,000 $355,000
Q1 2024

May 15, 2024

SELL
$28.03 - $51.82 $299,921 - $554,474
-10,700 Reduced 28.46%
26,900 $1.21 Million
Q4 2023

Feb 14, 2024

SELL
$20.06 - $28.66 $4.05 Million - $5.78 Million
-201,770 Reduced 84.29%
37,600 $1.03 Million
Q3 2023

Nov 14, 2023

BUY
$20.13 - $27.29 $1.55 Million - $2.1 Million
76,869 Added 47.3%
239,370 $5.64 Million
Q2 2023

Aug 14, 2023

BUY
$18.33 - $27.18 $1.71 Million - $2.54 Million
93,342 Added 134.97%
162,501 $4.28 Million
Q1 2023

May 15, 2023

BUY
$14.25 - $20.5 $339,135 - $487,879
23,799 Added 52.47%
69,159 $1.27 Million
Q4 2022

Feb 14, 2023

SELL
$12.8 - $23.66 $1.09 Million - $2.01 Million
-85,032 Reduced 65.21%
45,360 $701,000
Q3 2022

Nov 14, 2022

SELL
$18.64 - $28.93 $232,739 - $361,219
-12,486 Reduced 8.74%
130,392 $2.61 Million
Q2 2022

Aug 15, 2022

BUY
$13.98 - $29.25 $813,006 - $1.7 Million
58,155 Added 68.64%
142,878 $3.24 Million
Q1 2022

May 16, 2022

BUY
$23.58 - $30.91 $736,238 - $965,102
31,223 Added 58.36%
84,723 $2.24 Million
Q4 2021

Feb 14, 2022

BUY
$20.0 - $32.29 $1.07 Million - $1.73 Million
53,500 New
53,500 $1.7 Million

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.16B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.